DISCLAIMER: THIS PAGE IS INTENDED FOR HEALTHCARE PROFESSIONALS IN Czech Republic ONLY.

Information about the NuvaxovidTM XBB.1.5 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601)

NuvaxovidTM XBB.1.5 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601) has been granted full approval by the European Commission for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older.

Report an Adverse Event (AE)

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system of Czech Republic.

Státní ústav pro kontrolu léčiv
Šrobárova 48
100 41 Praha 10
Webové stránky: www.sukl.cz/nahlasit-nezadouci-ucinek

Contact Us

Tel: +420 228 880 267
09:00 - 17:00
Monday - Friday